A new study published in the International Journal of Infectious Diseases found that adjuvanted and high-dose flu vaccines provide similar protection against confirmed influenza infection and hospitalization in older adults. Both vaccine types are designed to strengthen immune responses in people aged 65 and older, who face greater risks from severe flu complications. Adjuvanted vaccines contain an ingredient that enhances immune response, while high-dose vaccines contain increased amounts of viral antigen.
Researchers analyzed data from over 37,000 American adults aged 65 and older who received one of these two vaccines during the 2023–24 flu season. Among those who sought care for acute respiratory illness and were tested, approximately 8.5% tested positive for influenza. The study found no statistically significant difference in effectiveness between the two vaccine types, with results consistent with previous research from the 2022–23 season and a meta-analysis of 10 additional studies.
Source: Read the full story at CIDRAP
This summary was written with AI assistance from the linked source.
Send this to yourself, or to someone who should see it
Enter your email and we will send you a link to this article.
